OPRK1 (pS369) Antibody
221€ (50 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
OPRK1 (pS369) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx330230
tested applications
ELISA, WB, IHC
Description
OPRK1 (pS369) Antibody is a Rabbit Polyclonal against OPRK1 (pS369).
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | OPRK1 (pS369) |
| Host | Rabbit |
| Reactivity | Mouse, Rat |
| Recommended Dilution | ELISA: 1/10000, WB: 1/500 - 1/2000, IHC: 1/100 - 1/300. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified by affinity chromatography. |
| Size 1 | 50 µg |
| Size 2 | 100 µg |
| Form | Liquid |
| Tested Applications | ELISA, WB, IHC |
| Buffer | PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | OPRK1,KOR-1,Kappa receptor,OP2,KOP,KOPr,OPRK, K-OR-1 |
| Background | Antibody anti-OPRK1 |
| Status | RUO |
Descripción
OPRK1, or the kappa-opioid receptor, is a G protein-coupled receptor (GPCR) that binds endogenous opioid peptides such as dynorphins. It is widely expressed in the central nervous system, particularly in regions like the spinal cord, hypothalamus, and limbic system, where it modulates pain, stress responses, and mood. OPRK1 couples to Gi/o proteins, leading to inhibition of adenylate cyclase, decreased cAMP production, and reduced neurotransmitter release. Activation of OPRK1 produces analgesia, particularly in visceral and spinal pain pathways, and induces dysphoria and sedation. OPRK1 also plays a key role in stress-induced behaviors, drug addiction, and depression, where its activation can reduce dopamine release and inhibit reward pathways. Dysregulation of OPRK1 signaling contributes to chronic pain, addiction, and stress-related disorders. Kappa-opioid receptor agonists are being developed as non-addictive analgesics, while antagonists are under investigation for treating mood disorders, addiction, and stress resilience, positioning OPRK1 as a dual therapeutic target.
Related Products
Opioid Receptor Kappa 1 (OPRK1) Antibody
OPRK1 Antibody is a Rabbit Polyclonal Antibody against OPRK1.
Ver Producto
Opioid Receptor Kappa 1 (OPRK1) Antibody
Rabbit polyclonal antibody against OPRK1 protein. Immunogen region is C-terminal.
Ver Producto
Opioid Receptor Kappa 1 (OPRK1) Antibody
Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Receptor for dynorphins. May play a role in arousal and regulation of autonomic and neuroendocrine functions.
Ver Producto